as of 12-30-2025 3:55pm EST
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 23.3M | IPO Year: | 2020 |
| Target Price: | $7.00 | AVG Volume (30 days): | 502.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $3.99 | Next Earning Date: | 11-06-2025 |
| Revenue: | $21,746,000 | Revenue Growth: | 24.08% |
| Revenue Growth (this year): | -21.75% | Revenue Growth (next year): | -18.18% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$0.52
Shares
25,000
Total Value
$13,000.00
Owned After
27,000
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$0.53
Shares
60,000
Total Value
$31,800.00
Owned After
447,110
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$0.51
Shares
3,000
Total Value
$1,530.00
Owned After
379,204
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.52
Shares
50,000
Total Value
$25,995.00
Owned After
322,419
SEC Form 4
Director
Avg Cost/Share
$0.51
Shares
12,500
Total Value
$6,375.00
Owned After
31,098
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$0.67
Shares
5,500
Total Value
$3,685.00
Owned After
447,110
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$0.65
Shares
4,500
Total Value
$2,925.00
Owned After
447,110
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$0.60
Shares
5,000
Total Value
$3,000.00
Owned After
379,204
SEC Form 4
Director
Avg Cost/Share
$0.74
Shares
15,500
Total Value
$11,470.00
Owned After
31,098
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$0.75
Shares
13,500
Total Value
$10,110.00
Owned After
379,204
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Makes Brigid | ELUT | Director | Dec 17, 2025 | Buy | $0.52 | 25,000 | $13,000.00 | 27,000 | |
| Ferguson Matthew | ELUT | CHIEF FINANCIAL OFFICER | Dec 17, 2025 | Buy | $0.53 | 60,000 | $31,800.00 | 447,110 | |
| Mills C Randal | ELUT | PRESIDENT AND CEO | Dec 17, 2025 | Buy | $0.51 | 3,000 | $1,530.00 | 379,204 | |
| RAKIN KEVIN | ELUT | Director, 10% Owner | Dec 17, 2025 | Buy | $0.52 | 50,000 | $25,995.00 | 322,419 | |
| Colpman David | ELUT | Director | Dec 17, 2025 | Buy | $0.51 | 12,500 | $6,375.00 | 31,098 | |
| Ferguson Matthew | ELUT | CHIEF FINANCIAL OFFICER | Dec 2, 2025 | Buy | $0.67 | 5,500 | $3,685.00 | 447,110 | |
| Ferguson Matthew | ELUT | CHIEF FINANCIAL OFFICER | Dec 1, 2025 | Buy | $0.65 | 4,500 | $2,925.00 | 447,110 | |
| Mills C Randal | ELUT | PRESIDENT AND CEO | Nov 24, 2025 | Buy | $0.60 | 5,000 | $3,000.00 | 379,204 | |
| Colpman David | ELUT | Director | Nov 17, 2025 | Buy | $0.74 | 15,500 | $11,470.00 | 31,098 | |
| Mills C Randal | ELUT | PRESIDENT AND CEO | Nov 13, 2025 | Buy | $0.75 | 13,500 | $10,110.00 | 379,204 |
ELUT Breaking Stock News: Dive into ELUT Ticker-Specific Updates for Smart Investing
See how ELUT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ELUT Elutia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.